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Introduction
More than 70 million Americans have
prediabetes, an early stage in the hy-
perglycaemic continuum associated
with an increased risk of developing
future diabetes (Haffner 2003; Ford
et al. 2010) and vascular complica-
tions (Milman & Crandall 2011). The
retina is a unique site to study
the human microcirculation. Retinal
blood ﬂow is controlled by autoregu-
latory metabolic and pressure mecha-
nisms which are impaired in diabetes
and may contribute to retinopathy
and vision loss (Pournaras et al.
2008). Understanding the pathophysi-
ologic basis for changed blood vessel
responses across the hyperglycaemic
continuum is important for the discov-
ery of new treatments and preventive
strategies during early disease stages.
A ﬂickering light stimulus has been
used to assess retinal vascular dys-
function. In healthy individuals, ﬂick-
ering light stimulus increases retinal
blood ﬂow and blood vessel diameter
(Michelson et al. 2002; Dorner et al.
2003a; Nagel & Vilser 2004; Lott
et al. 2012), whereas in diabetic indi-
viduals, retinal vasodilation is attenu-
ated (Garhofer et al. 2004; Mandecka
et al. 2007; Bek et al. 2008; Nguyen
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ABSTRACT.
Purpose: In diabetes, endothelial dysfunction and subsequent structural damage to
blood vessels can lead to heart attacks, retinopathy and strokes. However, it is
unclear whether prediabetic subjects exhibit microvascular dysfunction indicating
early stages of arteriosclerosis and vascular risk. The purpose of this study was to
examine whether retinal reactivity may be impaired early in the hyperglycaemic
continuum and may be associated with markers of inﬂammation.
Methods: Individuals with prediabetes (n = 22), type 2 diabetes (n = 25) and
healthy age and body composition matched controls (n = 19) were studied. We
used the Dynamic Vessel Analyzer to assess retinal vasoreactivity (percentage
change in vessel diameter) during a ﬂickering light stimulation. Fasting highly sen-
sitive c-reactive protein (hs-CRP), a marker of inﬂammation, was measured in
blood plasma.
Results: Prediabetic and diabetic individuals had attenuated peak vasodilator and
relative amplitude changes in retinal vein diameters to the ﬂickering light stimulus
compared with healthy controls (peak dilation: prediabetic subjects 3.3 ± 1.8%,
diabetic subjects 3.3 ± 2.1% and controls 5.6 ± 2.6%, p = 0.001; relative ampli-
tude: prediabetic subjects 4.3 ± 2.2%, diabetic subjects 5.0 ± 2.6% and control
subjects 7.2 ± 3.2%, p = 0.003). Similar ﬁndings were observed in retinal arter-
ies. Levels of hs-CRP were not associated with either retinal vessel response
parameters.
Conclusion: Retinal reactivity was impaired in prediabetic and type 2 diabetic
individuals in parallel with reduced insulin sensitivity but not associated with levels
of hs-CRP. Retinal vasoreactivity measurements may be a sensitive tool to assess
early vascular risk.
Key words: ﬂickering light stimulation – prediabetes – retinal reactivity – type 2 diabetes – vaso-
dilation
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et al. 2009; Pemp et al. 2009a,b; Lott
et al. 2012), but it is unknown
whether retinal vascular impairment
exists in prediabetes.
Several studies indicate that inﬂam-
mation plays an important role in the
development of atherosclerosis and
diabetes (Mazzone et al. 2008; D’Souza
et al. 2009). While diabetes has been
associated with elevated inﬂammatory
biomarkers (Thomsen et al. 2010) as
well as impaired macrovascular reactiv-
ity (Toda et al. 2010), whether inﬂam-
mation is associated with retinal
microvascular dysfunction across the
hyperglycaemic continuum is not clear.
Thus, the purpose of this study was
to examine whether retinal reactivity
may be impaired early in the hypergly-
caemic continuum and may be associ-
ated with markers of inﬂammation
such as highly sensitive c-reactive pro-
tein (hs-CRP) levels. We hypothesized
that individuals with prediabetes have
an impaired retinal vasoreactivity and
that attenuated retinal reactivity would
be associated with higher levels of
hs-CRP.
Methods
Subjects
The study was approved by the Institu-
tional Review Board at Penn State
Hershey Medical Center and followed
the Tenets of the Declaration of Hel-
sinki. Middle aged to older non-smok-
ing individuals with prediabetes
(n = 22), type 2 diabetes (n = 25) and
body mass index (BMI) and age similar
matched healthy controls (n = 19)
between 21 and 75 years of age partici-
pated in this study (Table 1). Diagno-
sis of diabetes and prediabetes was
based on the American Diabetic Asso-
ciation’s new classiﬁcation standards
for prediabetes (HbA1c ‡5.7% and
<6.5%) and type 2 diabetes (HbA1c
‡6.5%) (2010). Subjects were recruited
through physician letters and ﬂyers in
the general community. After signing
informed consent, all subjects com-
pleted a medical history, physical
examination and ocular screening
which included a measurement of
visual acuity and intraocular pressure.
Subjects had a normal eye examination
with corrected acuity of 20 ⁄ 30 or better
and an intraocular pressure below
21 mmHg. Subjects were free from
stroke, coronary, heart, lung and eye
diseases (e.g. retinopathy, age-related
macular degeneration and glaucoma)
and were not morbidly obese (BMI
> 45 kg ⁄m2) or currently pregnant.
All subjects were non-smokers and
controls had no history of hyperten-
sion. Diabetic subjects’ blood pressures
(BPs) were controlled by medications.
Experimental design
This comparative study examined reti-
nal reactivity (i.e. changes in vessel
diameter to ﬂickering light) using the
Dynamic Vessel Analyzer (DVA) in
three groups of subjects (healthy con-
trols and individuals with prediabetes
and type 2 diabetes). Subjects refrained
from alcohol, caffeine (Terai et al.
2012) and exercise for 24 hr prior to
testing and fasted for approximately
10 hr prior to testing. Measurements
were taken in a dimly lit room at
room temperature. Individuals with
type 2 diabetes held their diabetic
medications on the morning of the
study. None of the prediabetic sub-
jects were on diabetic medications.
Aspirin and non-steroidal anti-inﬂam-
matory medications were held for
24 hr prior to the study. After a
15-min rest period, venous blood sam-
Table 1. Subject demographics.
Healthy
controls Prediabetes
Type 2
diabetes p-value
Number of subjects 19 22 25
Number of women ⁄men 12 ⁄ 7 12 ⁄ 10 16 ⁄ 9
Ethnicity (%)
Caucasian 100 95 92
African ⁄American 0 0 8
Asian 0 5 0
Age (years) 52 ± 9 60 ± 10* 56 ± 9 0.04
Weight (lbs.) 184 ± 45 183 ± 40 193 ± 41 0.69
BMI (kg ⁄m2) 28.4 ± 5.0 29.0 ± 5.5 30.5 ± 5.2 0.42
Fasting glucose (mg ⁄ dl) 85 ± 9 95 ± 11 123 ± 53* 0.001
Fasting insulin (IU ⁄ml) 4 ± 4 5 ± 3 18 ± 29* 0.02
Insulin sensitivity (units) 0.41 ± 0.05 0.39 ± 0.05 0.34 ± 0.06* 0.001
HbA1c (%) 5.3 ± 0.3 6.0 ± 0.3 7.5 ± 1.8* 0.001
Total cholesterol (mg ⁄ dl) 200 ± 34 206 ± 34 180 ± 39 0.04
Low-density lipoprotein (mg ⁄ l) 125 ± 28 128 ± 30 105 ± 36 0.03
High-density lipoprotein (md ⁄ dl) 55 ± 19 54 ± 16 48 ± 11 0.21
High- ⁄ low-ratio lipoproteins 3.8 ± 1.4 4.1 ± 1.2 4.0 ± 1.2 0.75
Triglycerides (mg ⁄ dl) 91 ± 36 129 ± 71 137 ± 61* 0.03
Medications
Oral diabetic (total % of
individuals on)
0 0 84* 0.001
Speciﬁcs – number of people on
Sulfonylureas 12
Glucophage 13
Thiazolidinediones 3
Dipeptidyl peptidase IV inhibitors 5
Insulin (total % of individuals on) 0 0 28* 0.001
Speciﬁcs – number of people on
Glucagon-like peptide agonist 4
Rapid acting insulin 2
Long acting insulin 4
Antihypertension
(total % of individuals on)
0 32* 802* 0.001
Speciﬁcs – number of people on
Hydrochlorothiazide 2 3
Ace inhibitors 4 9
Beta-blockers 1 7
Calcium channel blockers 3 7
Alpha 2 adrenergic agonists 1 0
Angiotensin II receptors blockers 1 3
Fish oil (%) 26 36 16 0.28
Statins (%) 0 23* 68* 0.001
BMI = body mass index; Hb = haemoglobin; Mean ± SD.
* Signiﬁcantly different from controls.
 Signiﬁcantly different from prediabetic individuals.
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ples of hs-CRP, glucose, insulin, lipid
panel and HbA1c were drawn from
the brachial antecubital location for
later analysis. The eye with the best
visual acuity was dilated with one or
two drops of tropicamide (1%) and, if
needed, phenylephrine (2.5%) was
added to obtain optimal dilation.
Experimental protocol
After a rest period of 20 min to allow
stabilization of baseline parameters,
the subject’s retinal vessels were
imaged continuously for a total of
350 seconds. This protocol consisted
of a 50-second baseline period, fol-
lowed by three cycles consisting of a
ﬂickering light period (light ﬂashes at
a 12.5-Hz frequency for 20 seconds)
followed by a 80-second rest period
(Mandecka et al. 2007; Nguyen et al.
2009; Lott et al. 2012). BP and heart
rate (HR) were measured continuously
during the studies.
Measurements
Retinal vessel diameters
The DVA (Imedos Inc., Jena, Ger-
many) uses a modiﬁed fundus camera
(Zeiss FF450; Zeiss, Jena, Germany)
and a video recording unit. The system
visualizes retinal diameters in real time
and vessel calibres can be analysed off-
line (Garhofer et al. 2010). To obtain
images, the subject’s ﬁxation in the
fundus camera was adjusted so that
the optic nerve head was in the centre
of the fundus monitor. The fundus
cameras’ focus and green background
light were adjusted to provide crisp
images on the fundus monitor. The
region of interest (approximately
1.5 mm in length) was marked over a
superior or inferior temporal retinal
arteriole and venular between one and
two optic disc diameters from the
optic nerve disc. Selection criteria for
the chosen segments included main
vessels (segments >80 lm), a clear
contrast to fundus background, no
crossing or bifurcations and avoidance
of nearby vessels within one vessel
diameter of the chosen segment. This
region of interest was scanned at a fre-
quency of 25 times per second, and
measurements were reported in arbi-
trary units (AU). Eye-tracking tech-
nology in the DVA compensated for
small eye movements. Throughout the
testing, the subject was verbally
encouraged to maintain ﬁxation and
to blink frequently. All images were
stored on a VHS videotape recorder
for ofﬂine measurements. One obser-
ver analysed all measurements in a
standardized fashion using the DVA
software and corrected for any arte-
facts in the tracings due to spontane-
ous erroneous measurements.
Haemodynamics (HR and BP)
Heart rate, derived from the electro-
cardiogram, and BP were measured
continuously by use of a Finameter
device (model 2300; Ohmeda, Boulder,
CO, USA, conﬁrmed by an automated
sphygmomanometer, Dinamap; Criti-
kon, Tampa, FL, USA), and collected
online at 200 Hz.
Plasma bloods
Plasma hs-CRP levels were assayed
using radioimmunoassays (Diagnostic
Products Corp., Los Angeles, CA, USA).
Plasma glucose levels were assayed
using a colorimetric method (Ortho
Clinical Diagnostics, Auckland, New
Zealand), and insulin levels were
assayed using a chemiluminescent
immunoassay (Siemens Healthcare
Diagnostics Inc., Tarrytown, NY, USA).
Data analysis
For ﬂickering light trials, the resting
baseline was averaged from the last
15 seconds prior to each ﬂicker stimu-
lation. Peak vasodilation period was an
average of the highest diameters
achieved during ﬂicker and within
approximately the ﬁrst 3 seconds after
the stimulus ended to capture maxi-
mal vasodilation. Percentage change in
vessel diameter was calculated compar-
ing baseline diameter with the peak
diameter using the following equa-
tion: percentage change in diameter =
((diameterpeak)diameterbaseline) ⁄diame-
terbaseline) · 100). In addition, we mea-
sured maximal vasoconstriction after
peak vasodilation (i.e. lowest diameter
period was calculated by averaging
the three consecutive lowest diame-
ters after peak dilation). Lastly, we
calculated the range of diameter
change, known as relative amplitude
(percentage change in relative ampli-
tude = percentage change in peak
vasodilation + |percentage change in
vasoconstriction|; Lott et al. 2012).
Vessels chosen for analysis were local-
ized in the superior or inferior tempo-
ral quadrants. Quantitative insulin
sensitivity check index (QUICKI) was
calculated to assess insulin sensitivity
(IR = 1 ⁄ [(log insulin) + (log glucose)]
(Muniyappa et al. 2008) in all subjects.
Statistical analysis
From previous published retinal stud-
ies on healthy and diabetic populations
(Garhofer et al. 2004; Mandecka et al.
2007), power was calculated for a two-
group comparison (control versus pre-
diabetic or diabetic groups) for the
main outcome measure, a change in
retinal diameter. Using a one-way
analysis of variance for group compar-
isons, 18 subjects per group were calcu-
lated to yield a power of 98% to detect
a difference in retinal diameters. Anal-
yses of covariance were used to exam-
ine the effects of potential confounding
variables [i.e. age, mean arterial blood
pressure (MAP), and BMI] (Mandecka
et al. 2007; Kneser et al. 2009). Post
hoc testing was done with Bonferroni.
Repeated measures were performed for
examining changes in vital signs during
ﬂicker between groups. With the
groups’ data merged, the correlation
between two continuous variables (i.e.
changes in diameter to ﬂickering light
stimuli and hs-CRP) was assessed
using Pearson’s correlation coefﬁ-
cients. Statistical signiﬁcance was
accepted at p < 0.05, 95% conﬁdence
interval. All data were reported as
mean ± SD.
Table 2. Resting haemodynamics.
Subjects Healthy controls Prediabetes Type 2 diabetes p-value
HR (bpm) 62 ± 7 61 ± 9 68 ± 9 0.01
MAP (mmHg) 93 ± 9 93 ± 8 98 ± 10 0.04
SBP (mmHg) 121 ± 11 128 ± 15 133 ± 15* 0.03
DBP (mmHg) 79 ± 8 76 ± 7 81 ± 8 0.05
HR = heart rate; MAP = mean arterial pressure; SBP = systolic blood pressure; DBP = dia-
stolic blood pressure; Mean ± SD.
* Signiﬁcantly different from controls.
 Signiﬁcantly different from prediabetic individuals.
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Results
Subject characteristics
Groups were comparable in weight
and BMI (Table 1), but those with
prediabetes were slightly older than
the controls. The majority of the sub-
jects were Caucasian and women. Indi-
viduals had been diagnosed with
prediabetes for an average of 1 year or
type 2 diabetes for 6 years. Several
prediabetic individuals were using sta-
tin (23%) and antihypertensive ther-
apy (32%), but none used diabetic
medications. Most of the subjects with
diabetes were treated with oral diabetic
medications (84%), and several were
on combination therapy with long
and ⁄or short acting insulin (28%;
Table 1). Most of the diabetic subjects
were using single or multiple antihy-
pertensive (80%) and statin (68%)
therapy. All medications except beta-
blockers were held the morning of the
study. Diabetic subjects had higher
fasting glucose and HbA1c levels and
lower insulin sensitivity compared with
controls and prediabetic subjects. Dia-
betic compared with prediabetic sub-
jects had lower total cholesterols and
LDL levels. Type 2 diabetic subjects
had higher resting HR compared with
controls and prediabetic subjects.
Lastly, type 2 diabetic subjects had
slightly higher resting systolic and dia-
stolic BPs (Table 2).
Flicker light–induced vasodilation
Resting retinal artery and vein diame-
ters were similar at baseline between all
groups (artery: 116 ± 9 AU, 123 ± 20
AU, 118 ± 17 AU and vein: 139 ± 22
AU, 149 ± 19 AU, 148 ± 24 AU in
controls, prediabetic and type 2 dia-
betic subjects, respectively; differences
between groups p > 0.05). Flickering
light evoked vasodilation in all groups;
however, peak vein dilator responses
were attenuated in the prediabetic and
diabetic subjects compared with con-
trols (Fig. 1A). Despite no difference in
maximal vein vasoconstriction after
peak dilation, prediabetic and dia-
betic subjects compared with controls
also had attenuated relative ampli-
tude changes in venular diameter
(Fig. 1B,C). Similar ﬁndings were
observed for retinal arterioles
(Fig. 2A–C). Controlling for the cova-
riates (i.e. age, MAP and BMI) did not
alter the ﬁndings. There were no signiﬁ-
cant gender differences in arteriole or
venular vasodilator or vasoconstrictor
responses to the ﬂickering light stimu-
lus across all groups. Flickering light
stimuli did not signiﬁcantly change
resting HR or BP in any of the groups
(data not shown).
Glucose and insulin and BP effects on
vasodilation
When the control, prediabetic and
diabetic groups were combined, fast-
ing insulin and HbA1c levels were
associated with larger resting retinal
vein diameters (r = 0.25, p = 0.043
and r = 0.25, p = 0.046). There was
a trend towards an inverse relationship
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Fig. 1. Prediabetes and type 2 diabetes reduces retinal vein vasodilation to ﬂicker stimulus. Prediabetic and diabetic subjects compared with healthy
controls had attenuated retinal vein vasodilation responses to ﬂicker-induced stimuli (p = 0.001; A). There was no signiﬁcant difference in vein maxi-
mal vasoconstriction after peak vasodilation comparing the different groups (p = 0.07; B); however, the percentage change in relative amplitude in
dilation showed attenuated responses in prediabetic and diabetic subjects, compared with controls for the vein (p = 0.003; C). There was no differ-
ence between groups on time to maximal vein vasoconstrictor responses (data not shown; *Signiﬁcantly different from controls; p < 0.05; prediabet-
ics = PreDM; type 2 diabetics = Type 2 DM).
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Fig. 2. Type 2 diabetes reduces retinal artery vasodilation to ﬂicker stimulus. Type 2 diabetic subjects compared with controls had attenuated ret-
inal peak artery vasodilator response to the ﬂickering light stimulus (p = 0.015; A) with a greater maximal artery vasoconstrictor responses fol-
lowing the peak vasodilation compared with prediabetic subjects (p = 0.034; B). Prediabetic and type 2 diabetic individuals had a trend towards
reduced retinal artery amplitude compared with controls (p = 0.084; C). No difference between groups in time to maximal vasoconstrictor
responses was observed (data not shown); *Signiﬁcantly different from controls, p < 0.05; #Signiﬁcantly different from prediabetic group,
p < 0.05; prediabetics = PreDM; type 2 diabetics = Type 2 DM).
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between fasting insulin and venous
peak ﬂicker dilation (r = )0.23, p =
0.062) and relative amplitude change
in venular diameter (r = )0.21, p =
0.088) and HbA1c and arterial peak
ﬂicker dilation (r = )0.22, p =
0.082). Fasting insulin was also signiﬁ-
cantly correlated to resting HR and
MAP (r = 0.37 p = 0.002; r = 0.25,
p = 0.040, respectively). Insulin sensi-
tivity showed an inverse relationship to
BMI (r = )0.43, p = 0.0001), HR (r
= )0.36, p = 0.003), MAP (r =
)0.43, p = 0.0001), systolic BP
(r = )0.40, p = 0.001) and diastolic
BP (r = )0.37, p = 0.003). Lastly,
systolic BP was correlated to resting
vein diameters (r = 0.25, p = 0.069)
and inversely correlated to venous
diameter peak ﬂicker dilation (r =
)0.30, p = 0.014) and relative ampli-
tude change in venular diameter (r =
)0.32, p = 0.008, respectively). No
correlations in retinal reactivity and
the subjects’ lipid proﬁles were
detected.
Hs-CRP levels and vasodilation
There was no signiﬁcant difference in
plasma hs-CRP levels between groups
(Fig. 3). When the control, prediabetic
and diabetic groups were combined,
higher hs-CRP levels were associated
with smaller resting retinal artery
diameters (r = )0.30, p = 0.022). We
observed no signiﬁcant relationship
between hs-CRP levels and the magni-
tude of the artery or vein dilator
responses to ﬂicker (i.e. peak vasodila-
tion or relative amplitude; Fig. 4).
However, hs-CRP was signiﬁcantly
associated with BMI (r = 0.37,
p = 0.004).
Discussion
In this study, we examined retinal vas-
cular dilation responses to ﬂicker in
prediabetic and type 2 diabetic indi-
viduals and the relationship between
retinal vasodilator responses and an
inﬂammation biomarker (hs-CRP).
We found similar attenuated vasodila-
tor responses in individuals with pre-
diabetes and diabetes compared with
healthy controls. There was no rela-
tionship between ﬂicker-induced vaso-
dilation and hs-CRP levels. These
data suggest that prediabetic subjects
already have an impaired endothelial
function early in the disease which is
equivalent in magnitude to those
found in diabetic subjects and mecha-
nisms other than inﬂammatory hs-
CRP responses may be involved in
this early impairment.
Prediabetes, an early stage in the
hyperglycaemic continuum, is associ-
ated with a greater risk of later devel-
oping type 2 diabetes (Haffner 2003;
Ford et al. 2010; Milman & Crandall
2011) endothelial dysfunction and car-
diovascular risk (Ford et al. 2010). In
prediabetes and diabetes, both ele-
vated glucose and insulin levels can
lead to vasodilation of resting blood
vessels potentially through an increase
in vasodilators such as nitric oxide
(Muniyappa & Quon 2007). Our data
support prior retinal studies (Kiﬂey
et al. 2008; Sun et al. 2009) in which
higher HbA1c and insulin levels were
associated with larger retinal venular
diameters.
Previous studies examining retinal
vessel responses to ﬂickering light
stimuli in normal subjects demon-
strated robust increases in retinal
diameter and blood ﬂow responses
(Michelson et al. 2002; Dorner et al.
2003a,b; Nagel & Vilser 2004; Lott
et al. 2012), whereas diabetic individu-
als had an attenuated retinal dila-
tor responses (Garhofer et al. 2004;
Mandecka et al. 2007; Bek et al. 2008;
Nguyen et al. 2009; Pemp et al.
2009a,b; Lott et al. 2012). In addition,
retinal attenuation further increased
with the progression of diabetic reti-
nopathy (Mandecka et al. 2007; Tilma
& Bek 2012). Retinal vascular dys-
function is proposed to contribute to
the pathogenesis of diabetic retinopa-
thy (Schmetterer & Wolzt 1999), but
the exact microvascular changes that
precede diabetes are not clearly under-
stood (Caballero 2005).
In our study, we conﬁrmed an
attenuated retinal vein vasodilator
response in type 2 diabetics and
showed that similar changes are
already present in prediabetic individ-
uals (diabetic individuals 3.3 ± 1.8%
and prediabetic individuals 3.3 ±
2.1%) compared with healthy controls
(5.6 ± 2.6%). Similar ﬁndings were
found in the retinal arterioles in
response to the ﬂickering light stimuli.
As aging, high BP and obesity are
associated with attenuated ﬂickering
light responses (Mandecka et al. 2007;
Kneser et al. 2009; Kotliar et al.
2011), we adjusted our analysis for
age, BP, and BMI as covariates but
the ﬁndings did not change with these
adjustments. Differences in ﬂicker
magnitude of our subject groups com-
pared with prior studies may reﬂect
the use of different ﬂicker light proto-
cols (duration and Hz) as well as the
recent change in classiﬁcation of pre-
diabetes and diabetes (2010). Similar
to our results, previous retinal studies
have shown that the ﬂicker response
was not associated with HbA1c, in
type 1 and type 2 diabetic individuals
(Garhofer et al. 2004; Mandecka et al.
2007). We also demonstrated that
lower insulin sensitivity was associ-
ated with an attenuated venous vaso-
dilator response. This is in agreement
with previous studies which showed
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Fig. 3. Highly sensitive c-reactive protein (hs-
CRP) levels similar across groups. There was
no signiﬁcant difference in hs-CRP levels
between healthy controls, prediabetic and
type 2 diabetic subjects (p = 0.71).
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Fig. 4. No correlation between retinal dila-
tion to ﬂicker response and hs-CRP. When
all groups were combined, there were no sig-
niﬁcant correlations between hs-CRP and
percentage change in peak arterial or venular
diameter to ﬂicker dilation (p = 0.98 and
p = 0.73, respectively).
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that a lower QUICKI index was asso-
ciated with type 2 diabetes (Katz
et al. 2000) and prediabetes (Festa
et al. 2003).
As it appears that prediabetic sub-
jects may have an increased cardiovas-
cular risk and may develop retinopathy,
we now see that individuals with pre-
diabetes also have altered retinal
microvascular function. Thus, moni-
toring retinal reactivity may be an
early marker of microvascular disease
or endothelial dysfunction that clini-
cians can follow non-invasively.
Reduced retinal vasodilation in
response to ﬂickering light in predia-
betes and diabetes may indicate sev-
eral underlying pathological processes.
These include impaired autoregulation
and endothelial dysfunction. Vascular
abnormalities may cause retinal dam-
age such as pericycte loss which may
change the release of local metabo-
lites. Animal and human studies sug-
gest that part of the ﬂickering light
vasodilation can be explained by an
increase in the production of nitric
oxide (Kondo et al. 1997; Dorner
et al. 2003b). The attenuated ﬂicker
response in diabetes has been sug-
gested to be partly due to reduced
nitric oxide (Schmetterer et al. 1997).
In a recent study, it was shown that
retinal vessels in persons with type 1
diabetes have similar responses to
exogenous NO as healthy controls
(Pemp et al. 2009a), implying that the
diabetic retinal endothelium is not less
sensitive to NO. Thus, other factors
may play a role in the altered vasore-
activity observed in prediabetes and
diabetes. The attenuated responses in
those with prediabetes and diabetes
could also be due to the arteries
already being in a dilated state to
meet metabolic demand. However, as
we found no signiﬁcant difference in
resting arteriolar and venular diame-
ters between groups, we do not think
that these vessels were predilated in
the diabetic or prediabetic subjects.
Lastly, impaired vasomotor responses
observed in those with prediabetes
and diabetes could result from
impaired signalling between the neuro-
sensory retina and the vessels. These
impaired neurosensory coupling mech-
anisms may include glial cell or retinal
barrier dysfunction and altered vascu-
lar endothelium growth factor signal-
ling pathways (Pournaras et al. 2008;
Antonetti et al. 2012).
Highly sensitive c-reactive protein,
a general index of inﬂammation, has
been primarily used in large epidemio-
logical studies. Hs-CRP is produced
by the liver and rises during inﬂam-
matory processes, at least in part due
to increased interleukin-6 produced
by macrophages and adipocytes. Ele-
vations of hs-CRP have been associ-
ated with increased risk of developing
diabetes (Doi et al. 2005; Dehghan
et al. 2007; Hu et al. 2009) and heart
disease (Wilson et al. 2008; Buckley
et al. 2009) and risk of a having a
myocardial infarction (Ridker 2004).
Elevated hs-CRP has also been asso-
ciated with elevated fasting glucose
(Wu et al. 2002; Aronson et al. 2004;
Nakanishi et al. 2005) and HbA1c
levels (Wu et al. 2002). However,
there are mixed ﬁndings of elevated
hs-CRP and prediabetes (Doi et al.
2005; Sabanayagam & Shankar 2011).
In our study, there were no signiﬁcant
differences between groups on hs-
CRP. Factors that may have affected
these results included the use of sta-
tins (Ridker et al. 1999; Tan et al.
2002) and good glycaemic control
(King et al. 2003) of our diabetic indi-
viduals and ⁄or obesity (Meng et al.
2007) in matching our controls to the
other groups. In our study, we did
see an association between higher hs-
CRP levels and smaller resting artery
diameters. However, in a large popu-
lation study of individuals with a
range of risk factors for coronary
artery disease, elevated hs-CRP levels
were associated with wider venules
(Klein et al. 2006; Wong et al. 2006).
Our study did not ﬁnd a signiﬁcant
correlation between hs-CRP and vaso-
dilator or constrictor responses to the
ﬂicker stimulus across the hyperglycae-
mic continuum. Other studies measur-
ing macrovascular function such as
brachial ﬂow–mediated vasodilation
have also not seen signiﬁcant associa-
tions with hs-CRP (Vita et al. 2004;
Kullo et al. 2007; Lippincott et al.
2008). As hs-CRP is only one of sev-
eral indices of inﬂammation, we can-
not totally exclude the effects of
inﬂammation on the changes that we
observed in the retinal vascular beds
of prediabetic and diabetic subjects.
Thus, altered retinal vasoreactivity
may prove to be a signiﬁcantly more
sensitive indicator of atherosclerosis
and vascular risk than plasma hs-
CRP.
Limitations of the study
First, it is possible that there were
differences in ocular perfusion pres-
sures between groups in which higher
ocular perfusion pressures would lead
to an attenuated dilator response.
Although intraocular pressures were
not directly measured at the study
visit, all subjects had recent eye
examinations in which intraocular
pressures were in the normal range
(<21 mmHg). In addition, our ﬁnd-
ings did not change when we used
BP as a covariate. Second, DVA
requires optimal pupil dilation. Some
of our prediabetic (27%) and diabetic
(52%) subjects required additional
dilation with the use of phenyleph-
rine, which theoretically could elevate
MAP through increasing sympathetic
stimulation; however, our ﬁndings
were still observed when these indi-
viduals were excluded from the analy-
sis. Thus, we do not feel that the use
of phenylephrine negatively impacted
our study results. Third, we were
only able to measure diameters, not
blood ﬂow, so it is possible that
velocity may be altered differently by
the ﬂicker stimulus; however, we
could not measure retinal blood
velocity. Lastly, our hs-CRP levels
were based on only a single measure-
ment. In addition, the lack of group
differences in hs-CRP may have been
due to our diabetic subjects current
statin use (Tan et al. 2002). As our
study was powered for the percentage
change in retinal diameter (observed
power was 81–95%), it may be that
a larger sample size may be needed
to see differences in hs-CRP between
groups. This may also help
to explain why our study showed
only trends for inverse relationships
between fasting insulin and vessel
diameter responses to ﬂicker.
In summary, we have demonstrated
that retinal reactivity is impaired in
both prediabetic and diabetic individ-
uals, compared with healthy controls.
The inﬂammatory biomarker, hs-
CRP, was not associated with changes
in retinal vasoreactivity. Retinal va-
soreactivity measurements may there-
fore be a more sensitive non-invasive
indicator of early stages of atheroscle-
rosis than traditional markers of car-
diovascular risk such as hs-CRP.
Prospective studies may determine
whether this change in individuals
with prediabetes is a harbinger of
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future cardiovascular disease or reti-
nopathy.
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